Stravencon

Stravencon is a London-based specialty pharmaceutical company dedicated to the development and commercialization of niche, high-value therapeutic products. The company focuses on "Value Added Medicines" (VAMs) that address unmet clinical needs, particularly in the fields of Central Nervous System (CNS) disorders and endocrinology. Their flagship product, Slenyto, is a pediatric-specific prolonged-release melatonin formulation approved for treating insomnia in children with Autism Spectrum Disorder and Smith-Magenis Syndrome. Stravencon utilizes a partnership-centric business model to navigate regulatory pathways and expand the reach of its specialized portfolio across Europe and other global markets. The firm emphasizes the revitalization of established molecules through innovative delivery systems and pediatric-friendly formulations.